Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 110
Filter
Add more filters

Country/Region as subject
Publication year range
1.
Proc Natl Acad Sci U S A ; 120(24): e2219292120, 2023 06 13.
Article in English | MEDLINE | ID: mdl-37276405

ABSTRACT

Plants have two endosymbiotic organelles originated from two bacterial ancestors. The transition from an independent bacterium to a successful organelle would have required extensive rewiring of biochemical networks for its integration with archaeal host. Here, using Arabidopsis as a model system, we show that plant D-aminoacyl-tRNA deacylase 1 (DTD1), of bacterial origin, is detrimental to organellar protein synthesis owing to its changed tRNA recognition code. Plants survive this conflict by spatially restricting the conflicted DTD1 to the cytosol. In addition, plants have targeted archaeal DTD2 to both the organelles as it is compatible with their translation machinery due to its strict D-chiral specificity and lack of tRNA determinants. Intriguingly, plants have confined bacterial-derived DTD1 to work in archaeal-derived cytosolic compartment whereas archaeal DTD2 is targeted to bacterial-derived organelles. Overall, the study provides a remarkable example of the criticality of optimization of biochemical networks for survival and evolution of plant mitochondria and chloroplast.


Subject(s)
Arabidopsis , Organelles , Organelles/metabolism , Mitochondria/metabolism , RNA, Transfer, Amino Acyl/metabolism , Chloroplasts/metabolism , RNA, Transfer/metabolism , Arabidopsis/genetics
2.
Nucleic Acids Res ; 51(6): 2516-2528, 2023 04 11.
Article in English | MEDLINE | ID: mdl-36652992

ABSTRACT

At meiosis, programmed meiotic DNA double-strand breaks are repaired via homologous recombination, resulting in crossovers (COs). From a large excess of DNA double-strand breaks that are formed, only a small proportion gets converted into COs because of active mechanisms that restrict CO formation. The Fanconi anemia (FA) complex proteins AtFANCM, MHF1 and MHF2 were previously identified in a genetic screen as anti-CO factors that function during meiosis in Arabidopsis thaliana. Here, pursuing the same screen, we identify FANCC as a new anti-CO gene. FANCC was previously only identified in mammals because of low primary sequence conservation. We show that FANCC, and its physical interaction with FANCE-FANCF, is conserved from vertebrates to plants. Further, we show that FANCC, together with its subcomplex partners FANCE and FANCF, regulates meiotic recombination. Mutations of any of these three genes partially rescues CO-defective mutants, which is particularly marked in female meiosis. Functional loss of FANCC, FANCE, or FANCF results in synthetic meiotic catastrophe with the pro-CO factor MUS81. This work reveals that FANCC is conserved outside mammals and has an anti-CO role during meiosis together with FANCE and FANCF.


The Fanconi Anemia (FA) pathway is the subject of intense interest owing to the role of FA as a tumor suppressor. Three FA complex proteins, FANCM, MHF1 and MHF2, were identified as factors that suppress crossover during meiosis in the model plant Arabidopsis thaliana. Here, the authors extended these findings and identified a novel anti-crossover factor and showed that it encodes the plant FANCC homolog, which was previously thought to be vertebrate-specific. They further showed that FANCC regulates meiotic crossover together with two other FA proteins, FANCE and FANCF. This suggests that the FANCC­E­F subcomplex was already regulating DNA repair in the common ancestor of all living eukaryotes.


Subject(s)
Fanconi Anemia Complementation Group C Protein , Fanconi Anemia Complementation Group F Protein , Fanconi Anemia Complementation Group Proteins , Meiosis , Humans , Arabidopsis/genetics , Arabidopsis/metabolism , DNA/metabolism , Fanconi Anemia Complementation Group C Protein/genetics , Fanconi Anemia Complementation Group C Protein/metabolism , Fanconi Anemia Complementation Group F Protein/genetics , Fanconi Anemia Complementation Group F Protein/metabolism , Fanconi Anemia Complementation Group Proteins/genetics , Fanconi Anemia Complementation Group Proteins/metabolism , Homologous Recombination
3.
Oncology ; 102(3): 260-270, 2024.
Article in English | MEDLINE | ID: mdl-37699367

ABSTRACT

INTRODUCTION: Renal cell carcinoma (RCC) is the ninth most common cancer worldwide, with clear cell RCC (ccRCC) being the most frequent histological subtype. The tumor immune microenvironment (TIME) of ccRCC is an important factor to guide treatment, but current assessments are tissue-based, which can be time-consuming and resource-intensive. In this study, we used radiomics extracted from clinically performed computed tomography (CT) as a noninvasive surrogate for CD68 tumor-associated macrophages (TAMs), a significant component of ccRCC TIME. METHODS: TAM population was measured by CD68+/PanCK+ ratio and tumor-TAM clustering was measured by normalized K function calculated from multiplex immunofluorescence (mIF). A total of 1,076 regions on mIF slides from 78 patients were included. Radiomic features were extracted from multiphase CT of the ccRCC tumor. Statistical machine learning models, including random forest, Adaptive Boosting, and ElasticNet, were used to predict TAM population and tumor-TAM clustering. RESULTS: The best models achieved an area under the ROC curve of 0.81 (95% CI: [0.69, 0.92]) for TAM population and 0.77 (95% CI: [0.66, 0.88]) for tumor-TAM clustering, respectively. CONCLUSION: Our study demonstrates the potential of using CT radiomics-derived imaging markers as a surrogate for assessment of TAM in ccRCC for real-time treatment response monitoring and patient selection for targeted therapies and immunotherapies.


Subject(s)
Carcinoma, Renal Cell , Kidney Neoplasms , Humans , Carcinoma, Renal Cell/diagnostic imaging , Carcinoma, Renal Cell/pathology , Kidney Neoplasms/diagnostic imaging , Kidney Neoplasms/pathology , Tumor-Associated Macrophages/pathology , Radiomics , Tomography, X-Ray Computed/methods , Tumor Microenvironment
4.
Oncology ; 101(6): 375-388, 2023.
Article in English | MEDLINE | ID: mdl-37080171

ABSTRACT

INTRODUCTION: This study investigates how quantitative texture analysis can be used to non-invasively identify novel radiogenomic correlations with clear cell renal cell carcinoma (ccRCC) biomarkers. METHODS: The Cancer Genome Atlas-Kidney Renal Clear Cell Carcinoma open-source database was used to identify 190 sets of patient genomic data that had corresponding multiphase contrast-enhanced CT images in The Cancer Imaging Archive. 2,824 radiomic features spanning fifteen texture families were extracted from CT images using a custom-built MATLAB software package. Robust radiomic features with strong inter-scanner reproducibility were selected. Random forest, AdaBoost, and elastic net machine learning (ML) algorithms evaluated the ability of the selected radiomic features to predict the presence of 12 clinically relevant molecular biomarkers identified from the literature. ML analysis was repeated with cases stratified by stage (I/II vs. III/IV) and grade (1/2 vs. 3/4). 10-fold cross validation was used to evaluate model performance. RESULTS: Before stratification by tumor grade and stage, radiomics predicted the presence of several biomarkers with weak discrimination (AUC 0.60-0.68). Once stratified, radiomics predicted KDM5C, SETD2, PBRM1, and mTOR mutation status with acceptable to excellent predictive discrimination (AUC ranges from 0.70 to 0.86). CONCLUSIONS: Radiomic texture analysis can potentially identify a variety of clinically relevant biomarkers in patients with ccRCC and may have a prognostic implication.


Subject(s)
Carcinoma, Renal Cell , Kidney Neoplasms , Humans , Carcinoma, Renal Cell/diagnostic imaging , Carcinoma, Renal Cell/genetics , Carcinoma, Renal Cell/pathology , Kidney Neoplasms/diagnostic imaging , Kidney Neoplasms/genetics , Kidney Neoplasms/pathology , Reproducibility of Results , Tomography, X-Ray Computed/methods , Machine Learning , Retrospective Studies
5.
Biochem Biophys Res Commun ; 551: 121-126, 2021 04 30.
Article in English | MEDLINE | ID: mdl-33725573

ABSTRACT

We have investigated the mechanism of action of SWITCH1/DYAD (SWI1), an important regulator of plant meiosis in Arabidopsis that is required for meiotic chromosome organization including maintenance of sister chromatid cohesion. The central portion of SWI1 contains a domain of unknown function that shows strong conservation between SWI1 and its orthologs in maize and rice and is also found in paralogs including MALE MEIOCYTE DEATH 1 (MMD1). In order to examine the role of this domain we performed domain swap experiments into SWI1 in a swi1 mutant background. Domain swap analysis revealed functional conservation of the central domain between SWI1 and its orthologs but not with the domain from MMD1 suggesting that the domain plays an important role in SWI1 function that has been conserved in orthologs and diverged in paralogs in plant evolution. Analysis of expression of the non-complementing MMD1 domain swap SWI1(DSMMD1)::GFP transgenic lines revealed an altered pattern of expression that suggests a role for SWI1 in commitment to female meiocyte differentiation and meiosis. The results suggest that SWI1 may also play a developmental role as an identity determinant in the female germ cell lineage in addition to its known role in meiotic chromosome organization.


Subject(s)
Arabidopsis Proteins/metabolism , Arabidopsis/cytology , Cell Cycle Proteins/metabolism , Cell Differentiation , Ectopic Gene Expression , Meiosis , Nuclear Proteins/metabolism , Ovule/cytology , Protein Domains , Arabidopsis/genetics , Arabidopsis/metabolism , Arabidopsis Proteins/chemistry , Arabidopsis Proteins/genetics , Cell Cycle Proteins/chemistry , Cell Cycle Proteins/genetics , Cell Lineage , Gene Expression Regulation, Plant , Nuclear Proteins/chemistry , Nuclear Proteins/genetics , Oryza/genetics , Protein Domains/genetics , Sequence Alignment , Zea mays/genetics
6.
New Phytol ; 232(5): 1904-1908, 2021 12.
Article in English | MEDLINE | ID: mdl-34537960

ABSTRACT

Cantil is reported as a new-found organ specific to the model plant Arabidopsis thaliana that is prominent only in short-day-grown wild-type accessions or long-day-grown genetic mutants with delayed vegetative to reproductive transition. Here, we show that cantils (previously known as nubbins) arise as one of the many phenotypic consequences of aneuploidy resulting from chromosome dosage imbalances in Arabidopsis polyaneuploids despite normal reproductive transition in long-day photoperiods. Without a demonstrated function or adaptive significance, we view cantils as a morphological oddity rather than a separate organ, and as a manifestation of physiological perturbations triggered by genetic and environmental factors. We also note a striking phenotypic resemblance between 'cantil' and 'gynophore', a floral morphological structure that is naturally present in the allopolyploid Arabidopsis suecica.


Subject(s)
Arabidopsis , Arabidopsis/genetics , Benzilates , Flowers , Photoperiod , Piperidines
7.
Plant Physiol ; 184(3): 1499-1513, 2020 11.
Article in English | MEDLINE | ID: mdl-32859753

ABSTRACT

The ubiquitin-mediated proteasomal pathway regulates diverse cellular processes in plants by rapidly degrading target proteins, including the repressors of hormone signaling. Though ubiquitin proteases play a key role in this process by cleaving polyubiquitin chains to monomers, their function has not been studied in detail by mutational analysis. Here, we show that mutation in TARANI/UBIQUITIN-SPECIFIC PROTEASE14 (TNI/UBP14) leads to reduced auxin response and widespread auxin-related phenotypic defects in Arabidopsis (Arabidopsis thaliana). In a tni partial loss-of-function mutant that was originally isolated based on altered leaf shape, activity of the auxin-responsive reporters DR5::GUS, DR5::nYFP, and IAA2::GUS was reduced. Genetic interaction studies suggest that TNI is involved in auxin signaling and acts alongside TIR1, ARF7, and AUX1 Map-based cloning identified TNI as UBP14 Inefficient splicing of the mutant TNI transcript resulted in the formation of an inactive UBP14 protein, which led to accumulation of polyubiquitin chains and excess polyubiquitinated proteins in the mutant. In addition to the reduced auxin response, increased levels of DII:VENUS, IAA18:GUS, and HS::AXR3-NT:GUS were also observed in tni, perhaps due to inefficient polyubiquitin hydrolysis and proteasome-mediated degradation. Together, our study identifies a function for TNI/UBP14 in the auxin response through ubiquitin recycling.


Subject(s)
Arabidopsis/genetics , Arabidopsis/metabolism , Indoleacetic Acids/metabolism , Ubiquitin-Specific Proteases/genetics , Ubiquitin-Specific Proteases/metabolism , Ubiquitin/metabolism , Gene Expression Regulation, Plant , Genes, Plant , Genetic Variation , Genotype , Mutation , Ubiquitin/genetics
9.
Aesthet Surg J ; 39(7): NP253-NP258, 2019 06 21.
Article in English | MEDLINE | ID: mdl-30768141

ABSTRACT

Anaplastic large-cell lymphoma (ALCL) is a very rare but life-threatening complication that has largely been demonstrated to be associated with breast implants (BIA-ALCL). Patients are at risk of BIA-ALCL with the placement of breast implants for either cosmetic or reconstructive purposes, with the highest risks associated with textured breast implants. In the past decade, an increasing number of publications have focused on BIA-ALCL, but there has yet to be a reported case outside of the breast. Here, we describe a unique instance of gluteal implant-associated ALCL (GIA-ALCL) in a middle-aged woman. The patient received bilateral textured silicone gluteal implants only a year prior to her diagnosis of GIA-ALCL. The patient later presented to the Plastic and Reconstructive Surgery Department at our institution with ulceration at the site of her gluteal implants. Unfortunately, her condition deteriorated before explanation could be performed. Biopsy of a left lung mass demonstrated "hallmark" cells of ALCL ("horseshoe"-shaped nuclei). The diagnosis was verified by immunohistochemical testing that revealed expression of CD30, CD4, CD43, BCL6, Perforin, and Ki67 in a population of abnormal cells. The goals of this case report are thus to demonstrate that all patients undergoing implantation of textured silicone implants are at risk of developing ALCL and to provide evidence for the possible new diagnosis of GIA-ALCL. Level of Evidence: 5.


Subject(s)
Body Contouring/adverse effects , Buttocks/surgery , Lymphoma, Large-Cell, Anaplastic/etiology , Postoperative Complications/etiology , Prostheses and Implants/adverse effects , Biomarkers, Tumor/analysis , Biopsy , Body Contouring/instrumentation , Buttocks/diagnostic imaging , Fatal Outcome , Female , Humans , Lung/diagnostic imaging , Lung/pathology , Lymphoma, Large-Cell, Anaplastic/diagnosis , Lymphoma, Large-Cell, Anaplastic/pathology , Lymphoma, Large-Cell, Anaplastic/therapy , Magnetic Resonance Imaging , Middle Aged , Postoperative Complications/diagnosis , Postoperative Complications/pathology , Silicone Gels/adverse effects , Tomography, X-Ray Computed
10.
J Pathol ; 243(2): 220-229, 2017 10.
Article in English | MEDLINE | ID: mdl-28722111

ABSTRACT

Monoamine oxidase A (MAOA) is a mitochondrial enzyme that catalyzes oxidative deamination of neurotransmitters and dietary amines and produces H2 O2 . It facilitates the progression of gliomas and prostate cancer, but its expression and functional relevance have not been studied in lymphoma. Here, we evaluated MAOA in 427 cases of Hodgkin and non-Hodgkin lymphoma and in a spectrum of reactive lymphoid tissues by immunohistochemistry on formalin-fixed, paraffin-embedded specimens. MAOA was expressed by Hodgkin Reed-Sternberg (HRS) cells in the majority of classical Hodgkin lymphomas (cHLs) (181/241; 75%), with 34.8% showing strong expression. Weak MAOA was also noted in a minority of primary mediastinal large B-cell lymphomas (8/47; 17%) and in a mediastinal gray-zone lymphoma. In contrast, no MAOA was found in non-neoplastic lymphoid tissues, nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL; 0/8) or any other non-Hodgkin lymphomas studied (0/123). MAOA was more common in Epstein-Barr virus (EBV)-negative compared to EBV-positive cHL (p < 0.0001) and was especially prevalent in the EBV-negative nodular sclerosing subtype. Similar to primary human lymphoma specimens, most cHL-derived cell lines displayed MAOA activity, whereas non-Hodgkin-lymphoma-derived cell lines did not. The MAOA inhibitor clorgyline reduced the growth of L1236 cells and U-HO1 cells, and shRNA knockdown of MAOA reduced the growth of L1236 cells. Conversely, ectopic overexpression of MAOA increased the growth of MAOA-negative HDLM2 cells. Combined treatment with clorgyline and ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) was more effective in reducing cell growth than either regimen alone. In summary, MAOA is highly expressed in cHL and may reflect the distinct biology of this lymphoma. Further studies on the potential utility of MAOA as a diagnostic marker and therapeutic target are warranted. Copyright © 2017 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.


Subject(s)
Hodgkin Disease/enzymology , Monoamine Oxidase/metabolism , Cell Line, Tumor , Clorgyline/pharmacology , Epstein-Barr Virus Infections/enzymology , Female , Humans , Male , Middle Aged , Monoamine Oxidase Inhibitors/pharmacology , Reed-Sternberg Cells/metabolism
11.
PLoS Genet ; 11(9): e1005396, 2015 Sep.
Article in English | MEDLINE | ID: mdl-26348709

ABSTRACT

Meiosis produces haploid cells essential for sexual reproduction. In yeast, entry into meiosis activates transcription factors which trigger a transcriptional cascade that results in sequential co-expression of early, middle and late meiotic genes. However, these factors are not conserved, and the factors and regulatory mechanisms that ensure proper meiotic gene expression in multicellular eukaryotes are poorly understood. Here, we report that DUET/MMD1, a PHD finger protein essential for Arabidopsis male meiosis, functions as a transcriptional regulator in plant meiosis. We find that DUET-PHD binds H3K4me2 in vitro, and show that this interaction is critical for function during meiosis. We also show that DUET is required for proper microtubule organization during meiosis II, independently of its function in meiosis I. Remarkably, DUET protein shows stage-specific expression, confined to diplotene. We identify two genes TDM1 and JAS with critical functions in cell cycle transitions and spindle organization in male meiosis, as DUET targets, with TDM1 being a direct target. Thus, DUET is required to regulate microtubule organization and cell cycle transitions during male meiosis, and functions as a direct transcription activator of the meiotic gene TDM1. Expression profiling showed reduced expression of a subset comprising about 12% of a known set of meiosis preferred genes in the duet mutant. Our results reveal the action of DUET as a transcriptional regulator during male meiosis in plants, and suggest that transcription of meiotic genes is under stagewise control in plants as in yeast.


Subject(s)
Arabidopsis Proteins/genetics , Arabidopsis Proteins/physiology , Arabidopsis/genetics , Cyclins/genetics , DNA-Binding Proteins/physiology , Genes, Plant , Meiosis/genetics , Transcription Factors/physiology , Amino Acid Sequence , Arabidopsis Proteins/chemistry , Chromosomes, Plant , DNA-Binding Proteins/chemistry , Gene Expression Regulation, Plant , Humans , Molecular Sequence Data , Pollen , Sequence Homology, Amino Acid
12.
Plant Cell ; 26(4): 1612-1628, 2014 Apr.
Article in English | MEDLINE | ID: mdl-24737671

ABSTRACT

In flowering plants, meiocytes develop from subepidermal cells in anthers and ovules. The mechanisms that integrate gene-regulatory processes with meiotic programs during reproductive development remain poorly characterized. Here, we show that Arabidopsis thaliana plants deficient in ACTIN-RELATED PROTEIN6 (ARP6), a subunit of the SWR1 ATP-dependent chromatin-remodeling complex, exhibit defects in prophase I of female meiosis. We found that this meiotic defect is likely due to dysregulated expression of meiotic genes, particularly those involved in meiotic recombination, including DMC1 (DISRUPTED MEIOTIC cDNA1). Analysis of DMC1 expression in arp6 mutant plants indicated that ARP6 inhibits expression of DMC1 in the megasporocyte and surrounding nonsporogeneous ovule cells before meiosis. After cells enter meiosis, however, ARP6 activates DMC1 expression specifically in the megasporocyte even as it continues to inhibit DMC1 expression in the nonsporogenous ovule cells. We further show that deposition of the histone variant H2A.Z, mediated by the SWR1 chromatin-remodeling complex at the DMC1 gene body, requires ARP6. Therefore, ARP6 regulates female meiosis by determining the spatial and temporal patterns of gene expression required for proper meiosis during ovule development.

13.
Acta Haematol ; 138(3): 129-137, 2017.
Article in English | MEDLINE | ID: mdl-28866671

ABSTRACT

BACKGROUND: Autoimmune myelofibrosis (AIMF) is an underrecognized cause of nonmalignant bone marrow fibrosis which occurs in the presence or absence of a defined systemic autoimmune disease. Patients with AIMF present with cytopenias and autoantibodies, and have a distinctive nonclonal myelofibrosis on bone marrow examination. AIMF is distinguished from primary myelofibrosis by the absence of splenomegaly, eosinophilia, or basophilia, and the absence of abnormal myeloid, erythroid, or megakaryocytic morphology. OBJECTIVES: The objective of the study was to describe the clinical presentation and outcomes of patients with AIMF. METHODS: We conducted a single-institution, retrospective chart review of patients diagnosed with AIMF to investigate clinical presentations, therapies, and outcomes. RESULTS: Twelve patients with AIMF were identified with a mean follow-up of 5.8 years. All patients had detectable autoantibodies and the majority had concomitant autoimmune disorders. Four patients experienced a complete response of cytopenias and 3 patients experienced a partial response (PR) of cytopenias with immunosuppressive therapy. One patient achieved a PR following splenectomy. No patients were diagnosed with myeloproliferative neoplasms during the follow-up period. CONCLUSIONS: AIMF contributes to cytopenias in the subset of patients with various autoimmune disorders. The majority of patients with AIMF experience an improvement in cytopenias with immunosuppressive therapy.


Subject(s)
Autoimmune Diseases/pathology , Primary Myelofibrosis/pathology , Adult , Aged , Autoantibodies/analysis , Autoimmune Diseases/diagnosis , Autoimmune Diseases/drug therapy , Bone Marrow/pathology , Calreticulin/genetics , Female , Humans , Immunosuppressive Agents/therapeutic use , Janus Kinase 2/genetics , Male , Middle Aged , Polymorphism, Single Nucleotide , Primary Myelofibrosis/diagnosis , Primary Myelofibrosis/drug therapy , Receptors, Thrombopoietin/genetics , Retrospective Studies , Splenomegaly/complications , Splenomegaly/surgery , Treatment Outcome , Young Adult
14.
Mod Pathol ; 29(6): 570-81, 2016 06.
Article in English | MEDLINE | ID: mdl-26965583

ABSTRACT

A predominantly diffuse growth pattern and CD23 co-expression are uncommon findings in nodal follicular lymphoma and can create diagnostic challenges. A single case series in 2009 (Katzenberger et al) proposed a unique morphologic variant of nodal follicular lymphoma, characterized by a predominantly diffuse architecture, lack of the t(14;18) IGH/BCL2 translocation, presence of 1p36 deletion, frequent inguinal lymph node involvement, CD23 co-expression, and low clinical stage. Other studies on CD23+ follicular lymphoma, while associating inguinal location, have not specifically described this architecture. In addition, no follow-up studies have correlated the histopathologic and cytogenetic/molecular features of these cases, and they remain a diagnostic problem. We identified 11 cases of diffuse, CD23+ follicular lymphoma with histopathologic features similar to those described by Katzenberger et al. Along with pertinent clinical information, we detail their histopathology, IGH/BCL2 translocation status, lymphoma-associated chromosomal gains/losses, and assessment of mutations in 220 lymphoma-associated genes by massively parallel sequencing. All cases showed a diffuse growth pattern around well- to ill-defined residual germinal centers, uniform CD23 expression, mixed centrocytic/centroblastic cytology, and expression of at least one germinal center marker. Ten of 11 involved inguinal lymph nodes, 5 solely. By fluorescence in situ hybridization analysis, the vast majority lacked IGH/BCL2 translocation (9/11). Deletion of 1p36 was observed in five cases and included TNFRSF14. Of the six cases lacking 1p36 deletion, TNFRSF14 mutations were identified in three, highlighting the strong association of 1p36/TNFRSF14 abnormalities with this follicular lymphoma variant. In addition, 9 of the 11 cases tested (82%) had STAT6 mutations and nuclear P-STAT6 expression was detectable in the mutated cases by immunohistochemistry. The proportion of STAT6 mutations is higher than recently reported in conventional follicular lymphoma (11%). These findings lend support for a clinicopathologic variant of t(14;18) negative nodal follicular lymphoma and suggests importance of the interleukin (IL)-4/JAK/STAT6 pathway in this variant.


Subject(s)
Biomarkers, Tumor/genetics , Chromosome Disorders/genetics , Chromosomes, Human, Pair 14 , Chromosomes, Human, Pair 18 , Lymphoma, Follicular/genetics , Mutation , Receptors, IgE/analysis , Receptors, Tumor Necrosis Factor, Member 14/genetics , STAT6 Transcription Factor/genetics , Translocation, Genetic , Adult , Aged, 80 and over , Biomarkers, Tumor/analysis , Chromosome Deletion , Chromosome Disorders/immunology , Chromosome Disorders/pathology , Chromosomes, Human, Pair 1/genetics , Chromosomes, Human, Pair 1/immunology , DNA Mutational Analysis/methods , Female , Genes, Immunoglobulin Heavy Chain , Genetic Predisposition to Disease , High-Throughput Nucleotide Sequencing , Humans , Immunohistochemistry , In Situ Hybridization, Fluorescence , Lymphoma, Follicular/chemistry , Lymphoma, Follicular/immunology , Lymphoma, Follicular/pathology , Male , Middle Aged , Phenotype , Phosphorylation , Proto-Oncogene Proteins c-bcl-2/genetics , STAT6 Transcription Factor/analysis
15.
Ann Hematol ; 95(5): 733-8, 2016 Apr.
Article in English | MEDLINE | ID: mdl-26961933

ABSTRACT

Pegylated interferon α-2a (Peg-IFN) has been shown to induce hematologic and molecular responses in patients with the Philadelphia-negative myeloproliferative neoplasms (MPNs), including polycythemia vera (PV) and essential thrombocythemia (ET). We describe a series of patients with long-standing MPNs among whom Peg-IFN was initiated when they developed anemia and increased bone marrow reticulin fibrosis suggestive of early transformation to post-ET (PET) or post-PV (PPV) myelofibrosis (MF). Six patients were treated with Peg-IFN for a mean duration of 33.8 months (range 2-63 months). Five patients had long-standing ET (three were calreticulin (CALR)-positive, one janus kinase 2 (JAK2)-positive, and one JAK2-negative and CALR-negative), and one had long-standing JAK2-positive PV prior to starting Peg-IFN. This is the first study to report that, concurrent with the improvement in anemia, serial laboratory studies demonstrate an increase in serum LDH and left-shifted myeloid cells in the peripheral circulation over approximately 6 months, followed by a gradual normalization of these findings. Splenomegaly also increased and then resolved among responding patients. Serial bone marrow biopsies were available, which showed little change except for improvement in the grade of reticulin fibrosis in two patients. Among patients with early transformation to PET or PPV MF, our data support the efficacy of Peg-IFN in improving hemoglobin levels and reducing splenomegaly. These peripheral blood findings should not, therefore, be considered evidence of treatment failure within the first year of Peg-IFN therapy.


Subject(s)
Interferon-alpha/therapeutic use , Polyethylene Glycols/therapeutic use , Primary Myelofibrosis/drug therapy , Aged , Aged, 80 and over , Anemia/drug therapy , Anemia/etiology , Biomarkers , Bone Marrow/pathology , Bone Marrow Examination , Disease Progression , Drug Evaluation , Female , Hemoglobins/analysis , Humans , Interferon alpha-2 , L-Lactate Dehydrogenase/blood , Male , Middle Aged , Polycythemia Vera/complications , Polycythemia Vera/pathology , Primary Myelofibrosis/blood , Primary Myelofibrosis/etiology , Recombinant Proteins/therapeutic use , Reticulin/ultrastructure , Single-Blind Method , Splenomegaly/etiology , Splenomegaly/prevention & control , Thrombocythemia, Essential/complications , Thrombocythemia, Essential/genetics , Thrombocythemia, Essential/pathology
16.
Proc Natl Acad Sci U S A ; 110(29): 11988-93, 2013 Jul 16.
Article in English | MEDLINE | ID: mdl-23803853

ABSTRACT

Myc is one of the most commonly deregulated oncogenes in human cancer, yet therapies directly targeting Myc hyperactivation are not presently available in the clinic. The evolutionarily conserved function of Myc in modulating protein synthesis control is critical to the Myc oncogenic program. Indeed, enhancing the protein synthesis capacity of cancer cells directly contributes to their survival, proliferation, and genome instability. Therefore, inhibiting enhanced protein synthesis may represent a highly relevant strategy for the treatment of Myc-dependent human cancers. However, components of the translation machinery that can be exploited as therapeutic targets for Myc-driven cancers remain poorly defined. Here, we uncover a surprising and important functional link between Myc and mammalian target of rapamycin (mTOR)-dependent phosphorylation of eukaryotic translation initiation factor 4E binding protein-1 (4EBP1), a master regulator of protein synthesis control. Using a pharmacogenetic approach, we find that mTOR-dependent phosphorylation of 4EBP1 is required for cancer cell survival in Myc-dependent tumor initiation and maintenance. We further show that a clinical mTOR active site inhibitor, which is capable of blocking mTOR-dependent 4EBP1 phosphorylation, has remarkable therapeutic efficacy in Myc-driven hematological cancers. Additionally, we demonstrate the clinical implications of these results by delineating a significant link between Myc and mTOR-dependent phosphorylation of 4EBP1 and therapeutic response in human lymphomas. Together, these findings reveal that an important mTOR substrate is found hyperactivated downstream of Myc oncogenic activity to promote tumor survival and confers synthetic lethality, thereby revealing a unique therapeutic approach to render Myc druggable in the clinic.


Subject(s)
B-Lymphocytes/physiology , Benzoxazoles/pharmacology , Carrier Proteins/metabolism , Cell Transformation, Neoplastic/metabolism , Phosphoproteins/metabolism , Protein Biosynthesis/physiology , Proto-Oncogene Proteins c-myc/metabolism , Pyrimidines/pharmacology , TOR Serine-Threonine Kinases/metabolism , Adaptor Proteins, Signal Transducing , Animals , Benzoxazoles/administration & dosage , Blotting, Western , Cell Cycle Proteins , Eukaryotic Initiation Factors , Everolimus , Humans , Mice , Mice, Transgenic , Microarray Analysis , Phosphorylation , Pyrimidines/administration & dosage , Sirolimus/administration & dosage , Sirolimus/analogs & derivatives , TOR Serine-Threonine Kinases/antagonists & inhibitors
17.
Ann Diagn Pathol ; 21: 53-8, 2016 Apr.
Article in English | MEDLINE | ID: mdl-27040932

ABSTRACT

Patients with chronic myelogenous leukemia (CML) present typically with an elevated white blood cell count (WBC) and cytogenetic or molecular genetic evidence of t(9;22)/BCR-ABL1 fusion gene. Rarely, CML patients may present with a normal or mildly elevated WBC and are asymptomatic, and we describe 7 patients in this study. The WBC in these patients ranged from 3.6 to 14.3 K/mm(3) with 50% to 73% granulocytes and 0% blasts. In all patients, t(9;22)(q34;q11.2) was detected by conventional cytogenetics, and BCR-ABL1 fusion was shown, supporting the diagnosis of preleukemic CML (pre-CML). We compared these patients with a group of 5 cases of CML in chronic phase (CML-CP) and 5 bone marrow specimens with a leukemoid reaction (n=5). Reticulin, CD34, and CD61 immunostains were performed on all bone marrow biopsy specimens. Peripheral blood absolute basophilia (≥200/mm(3)) was noted in only 4 of 7 pre-CML cases, whereas it was present in all CML-CP cases and absent in leukemoid reaction cases. The mean ±SD of microvascular density of pre-CML cases (10.0 ± 4.3 vessels/200× field) was twice that of leukemoid reaction cases (5.0 ± 1.0) (P=.02; Student t test) but similar to that of CML-CP cases (12.5 ± 3.6). Microvessels in pre-CML, highlighted by CD34, were tortuous with abnormal branching, although to a lesser extent than those found in CML-CP. Microvessels in leukemoid reaction were generally straight. The percentage of small, hypolobated megakaryocytes, highlighted by CD61 in pre-CML, was 40%, 3 times that found in leukemoid reaction cases (13%) but less than that of CML-CP cases (86%). We conclude that pre-CML should be suspected in patients with a normal to mildly elevated WBC and absolute basophilia. Bone marrow examination can usually distinguish pre-CML from a leukemoid reaction based on the percentage of small, hypolobated megakaryocytes; microvascular density; and morphologic features.


Subject(s)
Biomarkers, Tumor/metabolism , Fusion Proteins, bcr-abl/genetics , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/diagnosis , Leukemoid Reaction/diagnosis , Philadelphia Chromosome , Adult , Aged , Bone Marrow/pathology , Female , Humans , In Situ Hybridization, Fluorescence , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/metabolism , Leukemoid Reaction/genetics , Leukemoid Reaction/metabolism , Leukocyte Count , Male , Megakaryocytes/pathology , Microvessels/pathology , Middle Aged
19.
BMC Plant Biol ; 15: 201, 2015 Aug 14.
Article in English | MEDLINE | ID: mdl-26272661

ABSTRACT

BACKGROUND: Retention of sister centromere cohesion during meiosis I and its dissolution at meiosis II is necessary for balanced chromosome segregation and reduction of chromosome number. PATRONUS1 (PANS1) has recently been proposed to regulate centromere cohesion in Arabidopsis after meiosis I, during interkinesis. pans1 mutants lose centromere cohesion prematurely during interkinesis and segregate randomly at meiosis II. PANS1 protein interacts with components of the Anaphase Promoting Complex/Cyclosome (APC/C). RESULTS: We show here that PANS1 protein is found mainly in prophase I of meiosis, with its level declining late in prophase I during diplotene. PANS1 also shows expression in dividing tissues. We demonstrate that, in addition to the previously reported premature loss of centromere cohesion during interkinesis, pans1 mutants show partially penetrant defects in centromere cohesion during meiosis I. We also determine that pans1 shows synthetic lethality at the level of the sporophyte, with Omission of Second Division 1 (osd1), which encodes a known inhibitor of the APC/C that is required for cell cycle progression during mitosis, as well as meiosis I and II. CONCLUSIONS: Our results show that PANS1 is expressed mainly in meiosis I where it has an important function and together with previous studies indicate that PANS1 and OSD1 are part of a network linking centromere cohesion and cell cycle progression through control of APC/C activity.


Subject(s)
Arabidopsis Proteins/genetics , Arabidopsis/genetics , Cell Cycle Proteins/genetics , Anaphase-Promoting Complex-Cyclosome/genetics , Anaphase-Promoting Complex-Cyclosome/metabolism , Arabidopsis/metabolism , Arabidopsis Proteins/metabolism , Cell Cycle Proteins/metabolism , Cell Nucleus/genetics , Centromere/genetics , Chromosome Segregation , Meiotic Prophase I
20.
Parasitology ; 141(10): 1341-52, 2014 Sep.
Article in English | MEDLINE | ID: mdl-25061727

ABSTRACT

Guanylate kinase, a nucleoside monophosphate kinase of Brugia malayi which is involved in reversible transfer of phosphate groups from ATP to GMP, was cloned, expressed and characterized. The native molecular mass of BmGK was found to be 45 kDa as determined by size exclusion chromatography and glutaraldehyde cross-linking which revealed that the protein is homodimer in nature. This is a unique characteristic among known eukaryotic GKs. GMP and ATP served as the most effective phosphate acceptor and donor, respectively. Recombinant BmGK utilized both GMP and dGMP, as substrates showing Km values of 30 and 38 µ m, respectively. Free Mg+2 (un-complexed to ATP) and GTP play a regulatory role in catalysis of BmGK. The enzyme showed higher catalytic efficiency as compared with human GK and showed ternary complex (BmGK-GMP-ATP) formation with sequential substrate binding. The secondary structure of BmGK consisted of 45% α-helices, 18% ß-sheets as revealed by CD analysis. Homology modelling and docking with GMP revealed conserved substrate binding residues with slight differences. Differences in kinetic properties and oligomerization of BmGK compared with human GK can provide the way for design of parasite-specific inhibitors.


Subject(s)
Filariasis/parasitology , Guanylate Kinases/metabolism , Nucleoside-Phosphate Kinase/metabolism , Animals , Brugia malayi/genetics , Dimerization , Guanylate Kinases/genetics , Guanylate Kinases/isolation & purification , Humans , Kinetics , Models, Molecular , Molecular Weight , Nucleoside-Phosphate Kinase/genetics , Nucleoside-Phosphate Kinase/isolation & purification
SELECTION OF CITATIONS
SEARCH DETAIL